The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a more aggressive form while under active surveillance. 

About The Study: In this population-level cohort study of 20 low-mortality countries, females ages 35 to 60 experienced disadvantage in cancer mortality compared with males—a consistent pattern observed across birth cohorts and over time. These findings underscore the ongoing need for action on the prevention, early detection, and treatment of early-onset female reproductive cancers. 

A new study has revealed a promising new approach to curb the spread of triple‑negative breast cancer, one of the most aggressive and difficult‑to‑treat forms of the disease.    

Published recently in Cancer Letters, Gabriel Duda, Ph.D., scientific director of transplant oncology and therapeutics at Houston Methodist Research Institute, and his research team discovered pairing targeted treatments with CAR T‑cell therapy may help control cancer recurrence when intervention options are otherwise limited. 

Proteins that are poorly soluble tend to clump together and have so far been nearly impossible to synthesise in the laboratory. ETH chemists have now found a way to link up poorly soluble protein fragments into complete proteins. The key to their success was a boron-containing compound that couples protein fragments much faster and therefore also at low concentrations. This method opens up a wide range of new possibilities, including for targeted cancer therapies or the incorporation of unnatural amino acids into proteins.